---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-257558"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2026-06-04T20:37:03+00:00"
generated_at: "2026-06-04T21:08:12.304490+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "low"
source: SEC EDGAR
---

# Fate updates corporate presentation for EULAR 2026; no specific new data in exhibit

## Summary
- Company filed an updated corporate presentation for use at the EULAR 2026 Congress on June 4, 2026.
- Presentation focuses on cell therapies for autoimmune diseases and cancer; ticker FATE listed on Nasdaq.
- No financial results, pipeline updates, or concrete milestones disclosed in the excerpted exhibit.
- Event is a routine update of investor materials; materiality is limited given lack of specific numbers.

## SEC filing metadata
- accession: 0001193125-26-257558
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2026-06-04T20:37:03+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000119312526257558/0001193125-26-257558-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000119312526257558/d83385d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-257558
- JSON: https://secwatch.observer/filing/0001193125-26-257558.json
- Plain text: https://secwatch.observer/filing/0001193125-26-257558.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.